Suicide and mental illness impact many lives in America. Current statistics reveal that over 14 million adults face serious mental illnesses, with around 8 million relying on medications. Alarmingly, suicide rates rose by 37% from 2000 to 2018. However, during my first term, we achieved a 5% decrease in these rates by 2020. Sadly, the COVID-19 pandemic reversed this progress. In 2022, rates peaked again, particularly affecting veterans, who face suicide rates more than double that of non-veterans.
Patients battling conditions like major depressive disorder often don’t respond well to traditional treatments. Despite significant federal funding aimed at advancing mental health research, we haven’t seen enough new therapies that provide lasting relief. This gap shows the need for innovative solutions.
Psychedelic substances, such as certain ibogaine compounds, are beginning to show promise in clinical studies. The FDA has even granted Breakthrough Therapy designations to some of these drugs, meaning they could play a crucial role in treating stubborn mental health conditions. It’s my goal to accelerate the research and approval process for these potentially life-saving medications.
Recent studies indicate that psychedelics may offer hope where conventional treatments fail. A report from the American Psychological Association highlighted that about 60% of participants saw improvements in their depression after psychedelic therapy. The promising results have sparked discussions about the role of psychedelics in mental health care.
The FDA is poised to facilitate patient access to these drugs under the Right to Try Act, ensuring that those in need can explore every option for recovery. We also plan to allocate at least $50 million to support state initiatives aimed at advancing the use of psychedelics for mental health treatment.
Collaboration among the Department of Health and Human Services, the FDA, and the Department of Veterans Affairs is essential. Together, we aim to increase clinical trial participation and share valuable data to speed up the development of effective therapies.
The Attorney General will also work with health officials to review and reschedule any psychedelic products that complete successful clinical trials. This will ensure that innovative treatments can quickly reach those who need them the most.
Our approach acknowledges the complexity of mental illness and strives for solutions that truly resonate with the struggles many face. Access to new treatments can pave the way for significant improvements in mental health care.
For further reading on mental health advancements and the potential role of psychedelics, check out the National Institutes of Health’s article on [mind-altering treatments for depression](https://www.nih.gov/news-events/news-releases/nih-funded-study-shows-psilocybin-treatment-results-sustained-improvement-depression).
